Latest information on COVID-19

Research Director

Dr. Bill Chiu

Dr. Bill Chiu has been performing biomedical research since 1993, utilizing animal models to study human diseases. Previously, he has developed an inflammation-based mouse model for abdominal aortic aneurysm and a rat model simulating portal vein obstruction to study coagulation factor alteration. Dr. Chiu's current focus is on pediatric solid tumors, especially neuroblastoma. He has developed various preclinical animal models for neuroblastoma, including orthotopic mouse models, patient derived xenograft models, and surgical resection models. These models are platforms for testing novel treatment strategies as well as tools to understand the mechanisms of tumor formation. Dr. Chiu’s laboratory is supported by the NIH, American College of Surgeons, and industry partners.

Mission Statement

To understand the mechanisms of pediatric solid tumors, precisely target the specific causes, and devise unique medical or surgical treatments for every child

Goals

Develop preclinical models that can faithfully recapitulate the tumor mechanism and microenvironment

Design, create, and develop different controlled release platforms that can be loaded with novel therapeutics and applied in solid tumors

Utilize molecular, genetic, immunological, bioengineering, and bioinformatics approaches to study mechanisms of tumor formation, progression, and metastasis

Develop minimally invasive protocol capable of precisely targeting solid tumor and improving surgical resection margins

 

Lab Members

Rachel Greathouse

Rachel Greathouse has been the Laboratory Manager for the Pediatric Oncology Laboratory since February 2020. She was first introduced to biomedical research in 2013 as a UC Davis undergraduate where she investigated a protein therapy for Angelman Syndrome. Prior to working at Stanford, Rachel had been a collaborative researcher at the UC Davis Veterinary Medical School between the Department of Pathology, Microbiology, and Immunology and Department of Medicine and Epidemiology. Her scientific background includes small and large animal medicine, veterinary endocrinology, stem cell biology, diabetes pathophysiology, and novel treatment development for genetic disorders. Her current projects in the Pediatric Oncology Laboratory primarily involve orthotopic preclinical modeling, advanced imaging techniques, surgical intervention, immunohistochemistry, confocal laser scanning microscopy, and testing of localized therapeutic delivery systems.

 

Email: rlgreat@stanford.edu

Abstracts and Presentations

Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment

"These results show that intratumoral chemotherapy delivery may be a treatment strategy for pediatric neuroblastoma, potentially translatable to other focal tumors types. Furthermore, this treatment modality allows for a clinically relevant mouse model of tumor transformation that may be used for studying the phenotypical tumor recurrence and developing more effective treatment strategies for recurrent tumors."